BioCardia financials
$1.03−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $58.0K | $477.0K | $1.4M | $1.0M | $145.0K | $710.0K | $625.0K | $479.0K | $576.0K |
| Gross profit | $0.00 | $58.0K | $477.0K | $1.4M | $1.0M | $141.0K | $352.0K | $108.0K | -$211.0K | -$170.0K |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 97.2% | 49.6% | 17.3% | −44.1% | −29.5% |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M | -$12.6M | -$15.5M | -$14.2M | -$14.1M | -$12.4M | -$7.6M |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M | -$12.6M | -$15.0M | -$14.7M | -$14.0M | -$12.3M | -$10.3M |
| Net margin | — | −13700.0% | −2425.8% | −880.7% | −1243.6% | −10347.6% | −2071.7% | −2237.9% | −2569.5% | −1789.9% |
| Diluted EPS | $-1.23 | $-2.90 | $-8.19 | $-10.05 | $-11.25 | $-22.20 | $-39.15 | $-49.20 | $-43.50 | $-18.45 |
| EBITDA | -$8.3M | -$7.9M | -$11.6M | -$11.5M | -$12.0M | -$15.5M | -$14.1M | -$14.0M | -$12.3M | -$7.6M |
| Operating cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.4M | -$12.4M | -$9.4M | -$11.1M | -$8.7M | -$5.5M |
| Free cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.5M | -$12.4M | -$9.6M | -$11.1M | -$8.8M | -$5.5M |
| Diluted shares | 6.7M | 2.7M | 1.4M | 1.2M | 1.1M | 0.7M | 0.4M | 0.3M | 0.3M | 0.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.5M | $2.4M | $1.1M | $7.4M | $12.9M | $21.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M | $15.7M | $23.4M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M | $5.3M | $4.2M |
| Shareholders' equity | $895.0K | $837.0K | -$1.6M | $4.9M | $10.4M | $19.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology